Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline
Eterna Therapeutics (ERNA) held its first Scientific Advisory Board meeting to advance its cell therapy pipeline, particularly focusing on induced mesenchymal stem cell (iMSC) therapy programs. The board, comprising experts including Michael Andreeff, Christopher Rohde, Blythe Sather, and Jerome B. Zeldis, reviewed the company's preclinical progress and strategic direction.
Key discussions centered on ERNA-101's positive preclinical data in ovarian cancer, including immune activation and tumor microenvironment interactions. The board aligned on advancing quality criteria, regulatory engagement, and clinical trial design. They explored potential combination therapies with CAR-T therapy and MUC16-targeting agents. Additionally, they evaluated ERNA-102's potential applications in autoimmune disease treatment.
Eterna Therapeutics (ERNA) ha tenuto il suo primo incontro del Comitato Scientifico Consultivo per avanzare nel suo pipeline di terapia cellulare, concentrandosi in particolare sui programmi di terapia con cellule staminali mesenchimali indotte (iMSC). Il comitato, composto da esperti tra cui Michael Andreeff, Christopher Rohde, Blythe Sather e Jerome B. Zeldis, ha esaminato i progressi preclinici dell'azienda e la direzione strategica.
Le discussioni chiave si sono concentrate sui dati preclinici positivi di ERNA-101 nel cancro ovarico, inclusa l'attivazione immunitaria e le interazioni con il microambiente tumorale. Il comitato si è allineato sull'avanzamento dei criteri di qualità, l'impegno normativo e la progettazione degli studi clinici. Hanno esplorato potenziali terapie di combinazione con la terapia CAR-T e agenti mirati a MUC16. Inoltre, hanno valutato le potenziali applicazioni di ERNA-102 nel trattamento delle malattie autoimmuni.
Eterna Therapeutics (ERNA) celebró su primera reunión del Consejo Asesor Científico para avanzar en su pipeline de terapia celular, centrándose particularmente en los programas de terapia con células madre mesenquimatosas inducidas (iMSC). El consejo, compuesto por expertos como Michael Andreeff, Christopher Rohde, Blythe Sather y Jerome B. Zeldis, revisó el progreso preclínico de la empresa y su dirección estratégica.
Las discusiones clave se centraron en los dátiles preclínicos positivos de ERNA-101 en cáncer de ovario, incluida la activación inmune y las interacciones con el microambiente tumoral. El consejo se alineó en avanzar en criterios de calidad, compromiso regulatorio y diseño de ensayos clínicos. Explorarion terapias de combinación potenciales con terapia CAR-T y agentes dirigidos a MUC16. Además, evaluaron las potenciales aplicaciones de ERNA-102 en el tratamiento de enfermedades autoinmunes.
에테르나 테라퓨틱스 (ERNA)는 세포 치료 파이프라인을 발전시키기 위해 첫 번째 과학 자문 위원회를 개최했으며, 특히 유도된 중간엽 줄기 세포(iMSC) 치료 프로그램에 중점을 두었습니다. 이 위원회는 Michael Andreeff, Christopher Rohde, Blythe Sather 및 Jerome B. Zeldis와 같은 전문가들로 구성되어 있으며, 회사의 전임상 진행 상황과 전략적 방향을 검토했습니다.
주요 논의는 ERNA-101의 긍정적인 전임상 데이터에 초점을 맞추었으며, 난소암에서의 면역 활성화 및 종양 미세환경 상호작용을 포함했습니다. 위원회는 품질 기준, 규제 참여 및 임상 시험 설계의 발전에 대해 의견을 일치시켰습니다. 그들은 CAR-T 치료 및 MUC16 표적 화합물과의 잠재적 병용 요법을 탐구했습니다. 또한, 그들은 자가면역 질환 치료에서 ERNA-102의 잠재적 응용을 평가했습니다.
Eterna Therapeutics (ERNA) a tenu sa première réunion du Conseil Consultatif Scientifique pour faire avancer son pipeline de thérapie cellulaire, en se concentrant particulièrement sur les programmes de thérapie par cellules souches mésenchymateuses induites (iMSC). Le conseil, composé d'experts tels que Michael Andreeff, Christopher Rohde, Blythe Sather et Jerome B. Zeldis, a examiné les progrès précliniques de l'entreprise et son orientation stratégique.
Les discussions clés ont porté sur les données précliniques positives d'ERNA-101 dans le cancer de l'ovaire, y compris l'activation immunitaire et les interactions avec le microenvironnement tumoral. Le conseil s'est mis d'accord sur l'avancement des critères de qualité, de l'engagement réglementaire et de la conception des essais cliniques. Ils ont exploré des thérapies combinées potentielles avec la thérapie CAR-T et des agents ciblant MUC16. De plus, ils ont évalué les applications potentielles d'ERNA-102 dans le traitement des maladies auto-immunes.
Eterna Therapeutics (ERNA) hielt sein erstes Treffen des Wissenschaftlichen Beirats ab, um seine Zelltherapie-Pipeline voranzutreiben, wobei der Schwerpunkt insbesondere auf Programmen zur Therapie mit induzierten mesenchymalen Stammzellen (iMSC) lag. Der Beirat, der aus Experten wie Michael Andreeff, Christopher Rohde, Blythe Sather und Jerome B. Zeldis besteht, überprüfte die präklinischen Fortschritte des Unternehmens und die strategische Ausrichtung.
Wichtige Diskussionen konzentrierten sich auf die positiven präklinischen Daten von ERNA-101 bei Eierstockkrebs, einschließlich der Immunaktivierung und der Wechselwirkungen mit der Tumormikroumgebung. Der Beirat einigte sich darauf, Qualitätskriterien, regulatorische Engagements und das Design klinischer Studien voranzutreiben. Sie erkundeten potenzielle Kombinationstherapien mit CAR-T-Therapie und MUC16-zielgerichteten Wirkstoffen. Darüber hinaus bewerteten sie die potenziellen Anwendungen von ERNA-102 in der Behandlung von Autoimmunerkrankungen.
- Positive preclinical data for ERNA-101 in ovarian cancer
- Strategic alignment on quality criteria and regulatory pathway
- Potential for combination therapies to enhance treatment efficacy
- Formation of high-profile Scientific Advisory Board with industry experts
- Products still in preclinical stage, requiring further studies
- Additional research needed to determine ERNA-102's efficacy
- Clinical trials yet to commence
Meeting addressed progress and strategic direction for company’s induced mesenchymal stem cell (iMSC) therapy programs
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced solid tumors and autoimmune diseases, today announced a successful inaugural meeting of its newly formed Scientific Advisory Board. The meeting brought together leading experts in cell therapy to evaluate preclinical advances, address key scientific questions, refine the company’s research and development priorities, and discuss the roadmap to human clinical trials.
The board consists of top leaders in the field, including:
- Michael Andreeff, MD, PhD, Professor in the Departments of Leukemia and Stem Cell Transplantation at The University of Texas MD Anderson Cancer Center
- Christopher Rohde, PhD, Co-founder and Chief Technology Officer of Factor Bioscience
- Blythe Sather, PhD, Vice President and Head of Research at Tune Therapeutics
- Jerome B. Zeldis, MD, PhD, held leadership roles at Celgene (now Bristol Myers Squibb) and NexImmune
“The meeting was truly invigorating, sparking dynamic discussions and strategic brainstorming on advancing our next-generation cell therapies to bring the greatest benefit to people battling cancer and autoimmune disease,” said Sanjeev Luther, CEO of Eterna Therapeutics. “It was inspiring to witness the board’s unparalleled expertise, combined with their unwavering passion and commitment to driving innovation with the highest level of scientific rigor.”
Some highlights from the meeting include:
- The board discussed the positive preclinical data for ERNA-101 in ovarian cancer, including immune activation, tumor microenvironment interactions, and potential combination strategies. Further studies are planned to optimize dose and route of administration in order to maximize downstream anti-tumor immune responses.
- The board was aligned on further advancing rigorous quality, safety, and efficacy criteria for product consistency, engaging with regulatory agencies, and prioritizing clinical trial design to accelerate the path to first-in-human studies.
- They also highlighted potential combination therapies with CAR-T therapy, MUC16-targeting agents, and other immunomodulatory approaches to enhance treatment efficacy in challenging disease areas.
- Lastly, the board focused on potential therapeutic indications within autoimmune disease for ERNA-102. Additional research will be conducted for further assessment.
Eterna will continue to collaborate with the Scientific Advisory Board and key stakeholders to translate these innovative therapies into impactful clinical practice.
About Eterna Therapeutics
Eterna Therapeutics (Nasdaq: ERNA) is developing innovative cell therapies for the treatment of advanced solid tumors and autoimmune diseases. Eterna’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Eterna’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.
Eterna is developing two highly innovative stem cell therapy products, both currently in pre-clinical stages. ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-102 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s primary focus is to develop ERNA-101 for the treatment of ovarian cancer.
For more information, visit www.eternatx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Eterna's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Eterna's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Eterna's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Eterna does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.
Media & Investor Relations Contact
FAQ
What were the key findings from ERNA's preclinical data for ERNA-101 in ovarian cancer?
What combination therapies is ERNA exploring for its cancer treatment program?
What is the current development status of ERNA-102 for autoimmune diseases?
Who are the key members of Eterna Therapeutics' Scientific Advisory Board?
